Efficacy News and Research

RSS
Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

New technique to treat metabolic disorders in babies while still in the womb

New technique to treat metabolic disorders in babies while still in the womb

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

URL Pharma's Colcrys approved by FDA for prevention of gout flares

URL Pharma's Colcrys approved by FDA for prevention of gout flares

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Durham VA Medical Center receives Daxor's BVA-100 Blood Volume Analyzer

Durham VA Medical Center receives Daxor's BVA-100 Blood Volume Analyzer

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

PLC Systems' RenalGuard to be utilized in a live case transmission at the GISE 2009 conference

PLC Systems' RenalGuard to be utilized in a live case transmission at the GISE 2009 conference

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.